Peter Ho
Impact in
- Oncology top 5%
- HER2/EGFR in Cancer Research
-
- Cancer Mechanisms and Therapy
Papers in
-
- Chromatin Remodeling and Cancer 7
- Cancer-related gene regulation 5
- Oncology 18
- HER2/EGFR in Cancer Research 9
- Cancer Treatment and Pharmacology 4
- Colorectal Cancer Treatments and Studies 3
- Co-authors
- Lei-Hua Liu (1 shared paper)Neil L. Spector (1 shared paper)Wenle Xia (1 shared paper)Malcolm A. Smith (2 shared papers)Richard Pazdur (1 shared paper)Steven Hirschfeld (1 shared paper)Stephen J. Blakemore (11 shared papers)Antoîne Italiano (8 shared papers)
- Journals
- Journal of Clinical Oncology (15 papers)Blood (5 papers)Chinese Journal of Cancer (2 papers)Cancer Research (2 papers)Investigational New Drugs (2 papers)
- Partner nations
- United StatesFranceNetherlands
In The Last Decade
Peter Ho
47 papers receiving 1.9k citations
Peter Ho's Hit Papers
Peers
Comparison fields: 5 of 90
- Oncology 684
- Pathology and Forensic Medicine 271
- Genetics 151
- Molecular Biology 1.0k
- Hematology 145
Countries citing papers authored by Peter Ho
This map shows the geographic impact of Peter Ho's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Ho with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Ho more than expected).
Fields of papers citing papers by Peter Ho
This network shows the impact of papers produced by Peter Ho. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Ho. The network helps show where Peter Ho may publish in the future.
Co-authors
The 25 scholars most cited alongside Peter Ho, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 48 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study Hit paper breakdown → | 2018 | 462 |
| 2 | 2004 | 198 | |
| 3 | 2003 | 170 | |
| 4 | 2017 | 128 | |
| 5 | 2008 | 89 | |
| 6 | 2016 | 72 | |
| 7 | 1993 | 68 | |
| 8 | 2005 | 64 | |
| 9 | 2010 | 60 | |
| 10 | 2010 | 52 | |
| 11 | 1995 | 50 | |
| 12 | 2007 | 49 | |
| 13 | 2017 | 43 | |
| 14 | 2015 | 42 | |
| 15 | 2021 | 37 | |
| 16 | 2015 | 33 | |
| 17 | Regulation of transferrin receptor in myeloid and monocytic differentiation of HL-60 leukemia cells. | 1989 | 30 |
| 18 | 2017 | 26 | |
| 19 | 2019 | 25 | |
| 20 | 1998 | 25 |
About Peter Ho
Peter Ho is a scholar working on Molecular Biology, Oncology, Pulmonary and Respiratory Medicine, Pathology and Forensic Medicine and Hematology, having authored 48 papers that have together received 2.0k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (9 papers), Chromatin Remodeling and Cancer (7 papers), Lung Cancer Treatments and Mutations (6 papers), Cancer-related gene regulation (5 papers), Cancer Mechanisms and Therapy (4 papers), Cancer Treatment and Pharmacology (4 papers), Microtubule and mitosis dynamics (3 papers) and Colorectal Cancer Treatments and Studies (3 papers). The work is most often cited by research in Oncology (684 citations), Pathology and Forensic Medicine (271 citations), Genetics (151 citations), Molecular Biology (1.0k citations) and Hematology (145 citations). Peter Ho has collaborated with scholars based in United States, France and Netherlands. Frequent co-authors include Lei-Hua Liu, Neil L. Spector, Wenle Xia, Malcolm A. Smith, Richard Pazdur, Steven Hirschfeld, Stephen J. Blakemore, Antoîne Italiano, Scott Ribich and Heike Keilhack. Their work appears in journals such as Journal of Clinical Oncology, Blood, Chinese Journal of Cancer, Cancer Research and Investigational New Drugs.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.